PTPI has 36-month beta value of 2.12. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PTPI is 9.13M, and currently, short sellers hold a 2.95% ratio of that float. The average trading volume of PTPI on December 26, 2024 was 1.55M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PTPI) stock’s latest price update
Petros Pharmaceuticals Inc (NASDAQ: PTPI) has experienced a rise in its stock price by 8.16 compared to its previous closing price of 0.29. However, the company has seen a fall of -11.25% in its stock price over the last five trading days. accesswire.com reported 2024-12-19 that Company positions itself for new innovation utilizing AI and quantum computing to help expand patient access to drugs via OTC access NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) (“Petros” or the “Company”), a company focused on expanding consumer access to medication through over the counter (“OTC”) drug development programs, today announced that in a recent podcast, The Intelligent Leadership Podcast, titled, “The New Era of Healthcare, AI, Data and Consumer Empowerment,” Petros President Fady Boctor discussed the Company’s concerted efforts to develop its proprietary platform as a prospective technology driven Rx-to-OTC switch solution across a multitude of conditions and existing Rx only therapies. During the podcast, Boctor discussed Petros’ technology tool development around a Drug Facts Label to self-select, as well as the utilization of AI to ensure safe engagement and access to a drug that has made the Rx-to-OTC switch.
PTPI’s Market Performance
PTPI’s stock has fallen by -11.25% in the past week, with a monthly rise of 7.45% and a quarterly drop of -7.21%. The volatility ratio for the week is 21.88% while the volatility levels for the last 30 days are 18.35% for Petros Pharmaceuticals Inc The simple moving average for the past 20 days is -3.68% for PTPI’s stock, with a -38.88% simple moving average for the past 200 days.
PTPI Trading at -3.23% from the 50-Day Moving Average
After a stumble in the market that brought PTPI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.27% of loss for the given period.
Volatility was left at 18.35%, however, over the last 30 days, the volatility rate increased by 21.88%, as shares surge +16.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.23% upper at present.
During the last 5 trading sessions, PTPI fell by -11.25%, which changed the moving average for the period of 200-days by -79.09% in comparison to the 20-day moving average, which settled at $0.3235. In addition, Petros Pharmaceuticals Inc saw -77.90% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PTPI
Current profitability levels for the company are sitting at:
- -3.38 for the present operating margin
- 0.73 for the gross margin
The net margin for Petros Pharmaceuticals Inc stands at -2.63. The total capital return value is set at -1.67. Equity return is now at value -91.54, with -33.16 for asset returns.
Based on Petros Pharmaceuticals Inc (PTPI), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at -0.8. The debt to equity ratio resting at 2.33. The interest coverage ratio of the stock is -26.17.
Currently, EBITDA for the company is -4.21 million with net debt to EBITDA at -3.37. When we switch over and look at the enterprise to sales, we see a ratio of 1.58. The receivables turnover for the company is 2.06for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.85.
Conclusion
To put it simply, Petros Pharmaceuticals Inc (PTPI) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
